Table 1 Inhibitory effect of MBIC against human cancerous and non-cancer cell-lines

  HeLa

0.21 ± 0.02

48.04

3.01 ± 0.03

2.66

3.08 ± 0.02

3.97

1.02 ± 0.01

6.57

0.46 ± 0.04

7.73

15.07 ± 0.03

1.23

  HCT-116

2.72 ± 0.4

3.70

5.34 ± 0.2

1.50

3.81 ± 0.6

3.20

3.09 ± 0.5

2.17

0.91 ± 0.2

3.91

7.22 ± 0.5

2.57

  A549

1.29 ± 0.07

7.82

7.78 ± 0.3

1.03

12.16 ± 0.2

1.00

2.83 ± 0.11

2.37

0.35 ± 0.07

10.17

34.04 ± 0.9

0.54

  HepG-2

2.92 ± 0.1

3.45

8.36 ± 0.9

0.95

10.71 ± 0.5

1.14

2.81 ± 0.72

2.38

8.04 ± 0.8

0.44

10.31 ± 0.5

1.80

  WRL-68

10.09 ± 1.2

8.02 ± 0.5

12.23 ± 0.9

6.71 ± 0.2

3.56 ± 0.9

18.6 ± 1.4

  HeLa

0.19 ± 0.03

37.68

2.02 ± 0.02

2.04

2.22 ± 0.04

3.40

0.57 ± 0.03

5.98

0.29 ± 0.04

5.79

9.02 ± 0.02

1.17

  HCT-116

2.01 ± 0.3

3.56

3.44 ± 0.2

1.20

1.81 ± 0.3

4.17

1.09 ± 0.4

3.12

0.47 ± 0.3

3.57

4.12 ± 0.6

2.56

  A549

0.53 ± 0.1

13.50

3.21 ± 0.7

1.28

5.09 ± 0.5

1.48

1.23 ± 0.09

2.77

0.09 ± 0.01

18.66

19.51 ± 1.4

0.54

  HepG-2

1.03 ± 0.09

6.95

4.08 ± 0.4

1.01

5.08 ± 0.3

1.48

1.03 ± 0.07

3.31

3.94 ± 0.07

0.42

5.93 ± 0.2

1.78

  WRL-68

7.16 ± 0.9

4.14 ± 0.7

7.56 ± 0.3

3.41 ± 0.8

1.68 ± 0.09

10.56 ± 0.7